LON:N4P

N4 Pharma Competitors

GBX 8.35
-0.25 (-2.91 %)
(As of 04/22/2021 03:13 PM ET)
Add
Compare
Today's Range
8.25
Now: GBX 8.35
8.70
50-Day Range
7.90
MA: GBX 8.44
9.48
52-Week Range
3.80
Now: GBX 8.35
16
Volume863,750 shs
Average Volume2.64 million shs
Market Capitalization£15.12 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

N4 Pharma (LON:N4P) Vs. AZN, GSK, DPH, HCM, VEC, and BXP

Should you be buying N4P stock or one of its competitors? Companies in the industry of "drug manufacturers - major" are considered alternatives and competitors to N4 Pharma, including AstraZeneca (AZN), GlaxoSmithKline (GSK), Dechra Pharmaceuticals (DPH), Hutchison China MediTech (HCM), Vectura Group (VEC), and Beximco Pharmaceuticals (BXP).

N4 Pharma (LON:N4P) and AstraZeneca (LON:AZN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Profitability

This table compares N4 Pharma and AstraZeneca's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
N4 PharmaN/AN/AN/A
AstraZenecaN/AN/AN/A

Earnings and Valuation

This table compares N4 Pharma and AstraZeneca's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
N4 Pharma£23,524.00642.76N/AGBX (1)-8.35
AstraZeneca£26.62 billion3.77N/AGBX 176.3043.41

N4 Pharma is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for N4 Pharma and AstraZeneca, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
N4 Pharma0000N/A
AstraZeneca501402.47

AstraZeneca has a consensus target price of GBX 8,757.06, indicating a potential upside of 14.59%. Given AstraZeneca's higher probable upside, analysts plainly believe AstraZeneca is more favorable than N4 Pharma.

Summary

AstraZeneca beats N4 Pharma on 5 of the 6 factors compared between the two stocks.

GlaxoSmithKline (LON:GSK) and N4 Pharma (LON:N4P) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares GlaxoSmithKline and N4 Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GlaxoSmithKlineN/AN/AN/A
N4 PharmaN/AN/AN/A

Valuation and Earnings

This table compares GlaxoSmithKline and N4 Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GlaxoSmithKline£34.10 billion1.99N/AGBX 114.1011.80
N4 Pharma£23,524.00642.76N/AGBX (1)-8.35

N4 Pharma is trading at a lower price-to-earnings ratio than GlaxoSmithKline, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for GlaxoSmithKline and N4 Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GlaxoSmithKline310502.11
N4 Pharma0000N/A

GlaxoSmithKline presently has a consensus price target of GBX 1,533.80, indicating a potential upside of 14.03%. Given GlaxoSmithKline's higher possible upside, analysts clearly believe GlaxoSmithKline is more favorable than N4 Pharma.

Summary

GlaxoSmithKline beats N4 Pharma on 5 of the 6 factors compared between the two stocks.

Dechra Pharmaceuticals (LON:DPH) and N4 Pharma (LON:N4P) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Dechra Pharmaceuticals and N4 Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dechra PharmaceuticalsN/AN/AN/A
N4 PharmaN/AN/AN/A

Valuation and Earnings

This table compares Dechra Pharmaceuticals and N4 Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dechra Pharmaceuticals£566.40 million7.47N/AGBX 41.4094.45
N4 Pharma£23,524.00642.76N/AGBX (1)-8.35

N4 Pharma is trading at a lower price-to-earnings ratio than Dechra Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Dechra Pharmaceuticals and N4 Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dechra Pharmaceuticals02202.50
N4 Pharma0000N/A

Dechra Pharmaceuticals presently has a consensus price target of GBX 3,350, indicating a potential downside of 14.32%. Given Dechra Pharmaceuticals' higher possible upside, analysts clearly believe Dechra Pharmaceuticals is more favorable than N4 Pharma.

Summary

Dechra Pharmaceuticals beats N4 Pharma on 5 of the 6 factors compared between the two stocks.

Hutchison China MediTech (LON:HCM) and N4 Pharma (LON:N4P) are both companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Hutchison China MediTech and N4 Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
N4 PharmaN/AN/AN/A

Valuation & Earnings

This table compares Hutchison China MediTech and N4 Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech£227.98 million13.64N/AGBX (13)-32.85
N4 Pharma£23,524.00642.76N/AGBX (1)-8.35

Hutchison China MediTech is trading at a lower price-to-earnings ratio than N4 Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Hutchison China MediTech and N4 Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech01002.00
N4 Pharma0000N/A

Summary

N4 Pharma beats Hutchison China MediTech on 3 of the 4 factors compared between the two stocks.

Vectura Group (LON:VEC) and N4 Pharma (LON:N4P) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Vectura Group and N4 Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vectura GroupN/AN/AN/A
N4 PharmaN/AN/AN/A

Valuation & Earnings

This table compares Vectura Group and N4 Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vectura Group£190.60 million3.55N/AGBX 20.105.64
N4 Pharma£23,524.00642.76N/AGBX (1)-8.35

N4 Pharma is trading at a lower price-to-earnings ratio than Vectura Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Vectura Group and N4 Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vectura Group01102.50
N4 Pharma0000N/A

Vectura Group currently has a consensus price target of GBX 134, indicating a potential upside of 18.21%. Given Vectura Group's higher possible upside, equities research analysts plainly believe Vectura Group is more favorable than N4 Pharma.

Summary

Vectura Group beats N4 Pharma on 5 of the 6 factors compared between the two stocks.

Beximco Pharmaceuticals (LON:BXP) and N4 Pharma (LON:N4P) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Beximco Pharmaceuticals and N4 Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Beximco Pharmaceuticals0000N/A
N4 Pharma0000N/A

Profitability

This table compares Beximco Pharmaceuticals and N4 Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Beximco PharmaceuticalsN/AN/AN/A
N4 PharmaN/AN/AN/A

Valuation & Earnings

This table compares Beximco Pharmaceuticals and N4 Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco PharmaceuticalsN/AN/AN/AN/AN/A
N4 Pharma£23,524.00642.76N/AGBX (1)-8.35

Summary

N4 Pharma beats Beximco Pharmaceuticals on 1 of the 1 factors compared between the two stocks.


N4 Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AstraZeneca logo
AZN
AstraZeneca
1.6$7,654.00-0.4%£100.03 billion£26.62 billion43.41Analyst Report
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.7$1,346.60-0.1%£67.82 billion£34.10 billion11.80Upcoming Earnings
Analyst Report
Dechra Pharmaceuticals logo
DPH
Dechra Pharmaceuticals
0.9$3,910.13-0.5%£4.25 billion£566.40 million94.45Insider Selling
Hutchison China MediTech logo
HCM
Hutchison China MediTech
0.6$427.00-2.2%£3.04 billion£227.98 million-32.85
Vectura Group logo
VEC
Vectura Group
1.4$113.36-0.7%£680.80 million£190.60 million5.64Dividend Increase
News Coverage
Beximco Pharmaceuticals logo
BXP
Beximco Pharmaceuticals
0.5$90.00-2.8%£390.35 millionN/A0.00
ECO Animal Health Group logo
EAH
ECO Animal Health Group
0.9$389.00-3.3%£253.98 million£86.32 million77.80
Allergy Therapeutics logo
AGY
Allergy Therapeutics
0.9$22.50-0.0%£144.18 million£81.76 million22.50
Futura Medical logo
FUM
Futura Medical
1.5$50.00-2.0%£120.36 million£31,778.00-50.00Gap Down
SAR
Sareum Holdings plc (SAR.L)
0.5$1.98-1.5%£63.72 million£47,204.00-7.15
CTI
Cathay International Holdings Limited (CTI.L)
0.8$0.75-33.3%£14.35 million£76.68 million3.75Gap Up
Sinclair Pharma logo
SPH
Sinclair Pharma
0.6$31.80-0.0%£0.00N/A0.00
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.